Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2012, Article ID 626094, 13 pages
http://dx.doi.org/10.1155/2012/626094
Review Article

Targeted Therapies in Sarcomas: Challenging the Challenge

1Laboratori d’Oncología Molecular, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), L’Hospitalet de Llobregat, 08908 Barcelona, Spain
2Nanomedicine Research Program, Molecular Biology and Biochemistry Research Center, CIBBIM-Nanomedicine, Vall d'Hebron Hospital Research Institute, 08035 Barcelona, Spain

Received 7 March 2012; Accepted 27 March 2012

Academic Editor: Peter Choong

Copyright © 2012 Juan Martín Liberal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Italiano, S. Mathoulin-Pelissier, A. Le Cesne et al., “Trends in survival for patients with metastatic soft-tissue sarcoma,” Cancer, vol. 117, no. 5, pp. 1049–1054, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. P. G. Casali and J. Y. Blay, “ESMO/CONTICANET/EUROBONET Consensus Panel of experts. Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 21, supplement 5, pp. v198–v203, 2010. View at Google Scholar
  3. E. Wardelmann, H. U. Schildhaus, S. Merkelbach-Bruse et al., “Soft tissue sarcoma: from molecular diagnosis to selection of treatment. Pathological diagnosis of soft tissue sarcoma amid molecular biology and targeted therapies,” Annals of Oncology, vol. 21, no. 7, pp. vii265–vii269, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. R. K. Jain, D. G. Duda, J. W. Clark, and J. S. Loeffler, “Lessons from phase III clinical trials on anti-VEGF therapy for cancer,” Nature Clinical Practice Oncology, vol. 3, no. 1, pp. 24–40, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. N. Ferrara, “Vascular endothelial growth factor: basic science and clinical progress,” Endocrine Reviews, vol. 25, no. 4, pp. 581–611, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Ferrara, “VEGF-A: a critical regulator of blood vessel growth,” European Cytokine Network, vol. 20, no. 4, pp. 158–163, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. J. A. Nagy, A. M. Dvorak, and H. F. Dvorak, “VEGF-A and the induction of pathological angiogenesis,” Annual Review of Pathology, vol. 2, pp. 251–275, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Potti, A. K. Ganti, K. Tendulkar et al., “Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcoma,” Journal of Cancer Research and Clinical Oncology, vol. 130, no. 1, pp. 52–56, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. U. Graeven, N. Andre, E. Achilles, C. Zornig, and W. Schmiegel, “Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma,” Journal of Cancer Research and Clinical Oncology, vol. 125, no. 10, pp. 577–581, 1999. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Chao, T. Al-Saleem, J. J. Brooks, A. Rogatko, W. G. Kraybill, and B. Eisenberg, “Vascular endothelial growth factor and soft tissue sarcomas: tumor expression correlates with grade,” Annals of Surgical Oncology, vol. 8, no. 3, pp. 260–267, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Iyoda, K. Hiroshima, M. Baba, T. Fujisawa, T. Yusa, and H. Ohwada, “Expression of vascular endothelial growth factor in thoracic sarcomas,” Annals of Thoracic Surgery, vol. 71, no. 5, pp. 1635–1639, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Shintani, A. Matsumine, K. Kusuzaki et al., “Expression of hypoxia-inducible factor (HIF)-1α as a biomarker of outcome in soft-tissue sarcomas,” Virchows Archiv, vol. 449, no. 6, pp. 673–681, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Comandone, A. Boglione, E. Berardengo et al., “Microvessel density (MVD) as a marker of neoangiogenesis: prognostic significance in correlation to grading and stage in adult soft tissue sarcoma (STS) of the extremities. A perspective study,” Proceedings of the American Society of Clinical Oncology, vol. 22, abstract 3303, 2003. View at Google Scholar
  14. C. C. West, N. J. Brown, D. C. Mangham, R. J. Grimer, and M. W. R. Reed, “Microvessel density does not predict outcome in high grade soft tissue sarcoma,” European Journal of Surgical Oncology, vol. 31, no. 10, pp. 1198–1205, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. N. C. Saenz, M. J. Heslin, V. Adsay et al., “Neovascularity and clinical outcome in high-grade extremity soft tissue sarcomas,” Annals of Surgical Oncology, vol. 5, no. 1, pp. 48–53, 1998. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Yudoh, M. Kanamori, K. Ohmori, T. Yasuda, M. Aoki, and T. Kimura, “Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas,” British Journal of Cancer, vol. 84, no. 12, pp. 1610–1615, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Stacchiotti, E. Tamborini, A. Marrari et al., “Response to sunitinib malate in advanced alveolar soft part sarcoma,” Clinical Cancer Research, vol. 15, no. 3, pp. 1096–1104, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. S. George, P. Merriam, R. G. Maki et al., “Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas,” Journal of Clinical Oncology, vol. 27, no. 19, pp. 3154–3160, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. S. T. Mahmood, S. Agresta, C. Vigil et al., “Phase II study of sunitinib malate, a multi-targeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on 3 prevalent histologies: Leiomyosarcoma, liposarcoma, and malignant fibrous histiocytoma,” International Journal of Cancer, vol. 129, pp. 1963–1969, 2010. View at Google Scholar
  20. M. L. Hensley, M. W. Sill, D. R. Scribner et al., “Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study,” Gynecologic Oncology, vol. 115, no. 3, pp. 460–465, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. X. Lu, X. Tang, W. Guo, T. Ren, and H. Zhao, “Sorafenib induces growth inhibition and apoptosis of human chondrosarcoma cells by blocking the RAF/ERK/MEK pathway,” Journal of Surgical Oncology, vol. 102, no. 7, pp. 821–826, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. Y. Pignochino, G. Grignani, G. Cavalloni et al., “Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways,” Molecular Cancer, vol. 8, article 118, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. W. Maruwge, P. D'Arcy, A. Folin et al., “Sorafenib inhibits tumor growth and vascularization of rhabdomyosarcoma cells by blocking IGF-1R-mediated signaling,” OncoTargets and Therapy, vol. 1, pp. 67–78, 2008. View at Google Scholar
  24. C. L. Peng, W. Guo, T. Ji et al., “Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway,” Cancer Biology and Therapy, vol. 8, no. 18, pp. 1729–1736, 2009. View at Google Scholar · View at Scopus
  25. G. Ambrosini, H. S. Cheema, S. Seelman et al., “Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells,” Molecular Cancer Therapeutics, vol. 7, no. 4, pp. 890–896, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Ardavanis, D. Doufexis, P. Kountourakis, and G. Rigatos, “A Kaposi's sarcoma complete clinical response after sorafenib administration,” Annals of Oncology, vol. 19, no. 9, pp. 1658–1659, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. U. Basso, A. Brunello, A. Bertuzzi, and A. Santoro, “Sorafenib is active on lung metastases from synovial sarcoma,” Annals of Oncology, vol. 20, no. 2, pp. 386–387, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. R. G. Maki, D. R. D'Adamo, M. L. Keohan et al., “Phase II study of sorafenib in patients with metastatic or recurrent sarcomas,” Journal of Clinical Oncology, vol. 27, no. 19, pp. 3133–3140, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. G. Grignani, E. Palmerini, P. Dileo et al., “A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an ItalianSarcoma Group study,” Annals of Oncology, vol. 23, pp. 508–516, 2012. View at Google Scholar
  30. M. Von Mehren, C. Rankin, J. R. Goldblum et al., “Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas,” Cancer, vol. 118, pp. 770–776, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Pacey, M. J. Ratain, K. T. Flaherty et al., “Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a phase II randomized discontinuation trial,” Investigational New Drugs, vol. 29, no. 3, pp. 481–488, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Sleijfer, I. Ray-Coquard, Z. Papai et al., “Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC Study 62043),” Journal of Clinical Oncology, vol. 27, no. 19, pp. 3126–3132, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. W Van-der-Graaf, J. Blay, S. P. Chawla et al., “PALETTE: a randomized, double-blind, phase III trial of pazopanib versus placebo in patients (pts) with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy—an EORTC STBSG Global Network Study (EORTC 62072),” Journal of Clinical Oncology, vol. 29, abstract LBA10002, 2011. View at Google Scholar
  34. A. C. Shor, E. A. Keschman, F. Y. Lee et al., “Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on Src kinase for survival,” Cancer Research, vol. 67, no. 6, pp. 2800–2808, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. F. Timeus, N. Crescenzio, A. Fandi, A. Doria, L. Foglia, and L. C. di Montezemolo, “In vitro antiproliferative and antimigratory activity of dasatinib in neuroblastoma and Ewing sarcoma cell lines,” Oncology Reports, vol. 19, no. 2, pp. 353–359, 2008. View at Google Scholar · View at Scopus
  36. P. Hingorani, W. Zhang, R. Gorlick, and E. A. Kolb, “Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo,” Clinical Cancer Research, vol. 15, no. 10, pp. 3416–3422, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. Y. M. Schrage, I. H. Briaire-de Bruijn, N. F. C. C. De Miranda et al., “Kinome profiling of chondrosarcoma reveals Src-pathway activity and dasatinib as option for treatment,” Cancer Research, vol. 69, no. 15, pp. 6216–6222, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Dalal, A. M. Berry, C. J. Cullinane et al., “Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma Family,” Clinical Cancer Research, vol. 11, no. 6, pp. 2364–2378, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Ferrario and C. J. Gomer, “Avastin enhances photodynamic therapy treatment of Kaposi's sarcoma in a mouse tumor model,” Journal of Environmental Pathology, Toxicology and Oncology, vol. 25, pp. 251–259, 2006. View at Google Scholar
  40. D. T. Vistica, M. Hollingshead, S. D. Borgel et al., “Therapeutic vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to antiangiogenic therapy,” Journal of Pediatric Hematology/Oncology, vol. 31, no. 8, pp. 561–570, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. A. L. Myers, R. F. Williams, C. Y. Ng, J. E. Hartwich, and A. M. Davidoff, “Bevacizumab-induced tumor vessel remodeling in rhabdomyosarcoma xenografts increases the effectiveness of adjuvant ionizing radiation,” Journal of Pediatric Surgery, vol. 45, no. 6, pp. 1080–1085, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. Y. Okada, T. Akisue, H. Hara et al., “The effect of bevacizumab on tumour growth of malignant fibrous histiocytoma in an animal model,” Anticancer Research, vol. 30, no. 9, pp. 3391–3395, 2010. View at Google Scholar · View at Scopus
  43. D. R. D'Adamo, S. E. Anderson, K. Albritton et al., “Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas,” Journal of Clinical Oncology, vol. 23, no. 28, pp. 7135–7142, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. C. F. Verschraegen, H. Arias-Pulido, S. J. Lee et al., “Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen,” Annals of Oncology, vol. 23, pp. 785–790, 2011. View at Google Scholar
  45. R. Gorlick, P. Anderson, I. Andrulis et al., “Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: Meeting Summary,” Clinical Cancer Research, vol. 9, no. 15, pp. 5442–5453, 2003. View at Google Scholar · View at Scopus
  46. A. Prieur, F. Tirode, P. Cohen, and O. Delattre, “EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3,” Molecular and Cellular Biology, vol. 24, no. 16, pp. 7275–7283, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. J. Khan, M. L. Bittner, L. H. Saal et al., “cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 23, pp. 13264–13269, 1999. View at Publisher · View at Google Scholar · View at Scopus
  48. D. Ayalon, T. Glaser, and H. Werner, “Transcriptional regulation of IGF-I receptor gene expression by the PAX3-FKHR oncoprotein,” Growth Hormone and IGF Research, vol. 11, no. 5, pp. 289–297, 2001. View at Publisher · View at Google Scholar · View at Scopus
  49. E. Karnieli, H. Werner, F. J. Rauscher, L. E. Benjamin, and D. Leroith, “The IGF-I receptor gene promoter is a molecular target for the Ewing's sarcoma-Wilms' tumor 1 fusion protein,” Journal of Biological Chemistry, vol. 271, no. 32, pp. 19304–19309, 1996. View at Publisher · View at Google Scholar · View at Scopus
  50. I. Finkeltov, S. Kuhn, T. Glaser et al., “Transcriptional regulation of IGF-I receptor gene expression by novel isoforms of the EWS-WT1 fusion protein,” Oncogene, vol. 21, no. 12, pp. 1890–1898, 2002. View at Publisher · View at Google Scholar · View at Scopus
  51. H. Werner, G. Idelman, M. Rubinstein, P. Pattee, S. R. Nagalla, and C. T. Roberts, “A novel EWS-WT1 gene fusion product in desmoplastic small round cell tumor is a potent transactivator of the insulin-like growth factor-I receptor (IGF-IR) gene,” Cancer Letters, vol. 247, no. 1-2, pp. 84–90, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. P. V. Pedone, R. Tirabosco, A. O. Cavazzana et al., “Mono- and bi-allelic expression of insulin-like growth factor II gene in human muscle tumors,” Human Molecular Genetics, vol. 3, no. 7, pp. 1117–1121, 1994. View at Google Scholar · View at Scopus
  53. H. Scrable, W. Cavenee, F. Ghavimi, M. Lovell, K. Morgan, and C. Sapienza, “A model for embryonal rhabdomyosarcoma tumorigenesis that involves genome imprinting,” Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 19, pp. 7480–7484, 1989. View at Google Scholar · View at Scopus
  54. M. Visser, C. Sijmons, J. Bras et al., “Allelotype of pediatric rhabdomyosarcoma,” Oncogene, vol. 15, no. 11, pp. 1309–1314, 1997. View at Google Scholar · View at Scopus
  55. S. Zhan, D. N. Shapiro, and L. J. Helman, “Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma,” Journal of Clinical Investigation, vol. 94, no. 1, pp. 445–448, 1994. View at Google Scholar · View at Scopus
  56. J. Anderson, A. Gordon, K. Pritchard-Jones et al., “Genes, chromosomes, and rhabdomyosarcoma,” Genes Chromosomes Cancer, vol. 26, pp. 275–285, 1999. View at Google Scholar
  57. Y. Sun, D. Gao, Y. Liu, J. Huang, S. Lessnick, and S. Tanaka, “IGF2 is critical for tumorigenesis by synovial sarcoma oncoprotein SYT-SSX1,” Oncogene, vol. 25, no. 7, pp. 1042–1052, 2006. View at Publisher · View at Google Scholar · View at Scopus
  58. D. R. H. De Bruijn, S. V. Allander, A. H. A. Van Dijk et al., “The synovial sarcoma-associated SS18-SSX2 fusion protein induces epigenetic gene (de)regulation,” Cancer Research, vol. 66, no. 19, pp. 9474–9482, 2006. View at Publisher · View at Google Scholar · View at Scopus
  59. D. N. Shapiro, B. G. Jones, L. H. Shapiro, P. Dias, and P. J. Houghton, “Antisense-mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma,” Journal of Clinical Investigation, vol. 94, no. 3, pp. 1235–1242, 1994. View at Google Scholar · View at Scopus
  60. K. Scotlandi, S. Avnet, S. Benini et al., “Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells,” International Journal of Cancer, vol. 101, no. 1, pp. 11–16, 2002. View at Publisher · View at Google Scholar · View at Scopus
  61. K. Scotlandi, S. Benini, P. Nanni et al., “Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice,” Cancer Research, vol. 58, no. 18, pp. 4127–4131, 1998. View at Google Scholar · View at Scopus
  62. E. Anders Kolb, R. Gorlick, P. J. Houghton et al., “Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program,” Pediatric Blood and Cancer, vol. 50, no. 6, pp. 1190–1197, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. T. Kalebic, M. Tsokos, and L. J. Helman, “In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34(cdc2),” Cancer Research, vol. 54, no. 21, pp. 5531–5534, 1994. View at Google Scholar · View at Scopus
  64. K. Scotlandi, M. C. Manara, G. Nicoletti et al., “Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors,” Cancer Research, vol. 65, no. 9, pp. 3868–3876, 2005. View at Publisher · View at Google Scholar · View at Scopus
  65. A. S. Martins, C. Mackintosh, D. Herrero Martín et al., “Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor,” Clinical Cancer Research, vol. 12, no. 11 I, pp. 3532–3540, 2006. View at Publisher · View at Google Scholar · View at Scopus
  66. M. C. Manara, L. Landuzzi, P. Nanni et al., “Preclinical in vivo study of new insulin-like growth factor-I receptor-specific inhibitor in Ewing's sarcoma,” Clinical Cancer Research, vol. 13, no. 4, pp. 1322–1330, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. L. Cao, Y. Yu, I. Darko et al., “Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody,” Cancer Research, vol. 68, no. 19, pp. 8039–8048, 2008. View at Publisher · View at Google Scholar · View at Scopus
  68. A. W. Tolcher, J. Sarantopoulos, A. Patnaik et al., “Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1,” Journal of Clinical Oncology, vol. 27, no. 34, pp. 5800–5807, 2009. View at Publisher · View at Google Scholar · View at Scopus
  69. D. Olmos, S. Postel-Vinay, L. R. Molife et al., “Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study,” The Lancet Oncology, vol. 11, no. 2, pp. 129–135, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. P. Schoffski, D. Adkins, J. Blay et al., “Phase II trial of anti-IGF-IR antibody cixutumumab in patients with advanced or metastatic soft-tissue sarcoma and Ewing family of tumors,” Journal of Clinical Oncology, vol. 29, abstract 10004, 2011. View at Google Scholar
  71. K. Scotlandi, M. C. Manara, G. Nicoletti et al., “Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors,” Cancer Research, vol. 65, no. 9, pp. 3868–3876, 2005. View at Publisher · View at Google Scholar · View at Scopus
  72. A. S. Martins, C. Mackintosh, D. Herrero Martín et al., “Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor,” Clinical Cancer Research, vol. 12, no. 11 I, pp. 3532–3540, 2006. View at Publisher · View at Google Scholar · View at Scopus
  73. M. C. Manara, L. Landuzzi, P. Nanni et al., “Preclinical in vivo study of new insulin-like growth factor-I receptor-specific inhibitor in Ewing's sarcoma,” Clinical Cancer Research, vol. 13, no. 4, pp. 1322–1330, 2007. View at Publisher · View at Google Scholar · View at Scopus
  74. P. Sabbatini, J. L. Rowand, A. Groy et al., “Antitumor activity of GSK1904529A, a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase,” Clinical Cancer Research, vol. 15, no. 9, pp. 3058–3067, 2009. View at Publisher · View at Google Scholar · View at Scopus
  75. P. Sabbatini, S. Korenchuk, J. L. Rowand et al., “GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers,” Molecular Cancer Therapeutics, vol. 8, no. 10, pp. 2811–2820, 2009. View at Publisher · View at Google Scholar · View at Scopus
  76. F. Huang, A. Greer, W. Hurlburt et al., “The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors,” Cancer Research, vol. 69, no. 1, pp. 161–170, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. N. Friedrichs, J. Küchler, E. Endl et al., “Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma,” Journal of Pathology, vol. 216, no. 4, pp. 428–439, 2008. View at Publisher · View at Google Scholar · View at Scopus
  78. Z. Duan, E. Choy, D. Harmon et al., “Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines,” Molecular Cancer Therapeutics, vol. 8, no. 8, pp. 2122–2130, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. X. Wan and L. J. Helman, “The biology behind mTOR inhibition in sarcoma,” Oncologist, vol. 12, no. 8, pp. 1007–1018, 2007. View at Publisher · View at Google Scholar · View at Scopus
  80. A. A. Samani, S. Yakar, D. LeRoith, and P. Brodt, “The role of the IGF system in cancer growth and metastasis: overview and recent insights,” Endocrine Reviews, vol. 28, no. 1, pp. 20–47, 2007. View at Publisher · View at Google Scholar · View at Scopus
  81. Y. Xie, B. Skytting, G. Nilsson, B. Brodin, and O. Larsson, “Expression of insulin-like growth factor-1 receptor in synovial sarcoma: association with an aggressive phenotype,” Cancer Research, vol. 59, no. 15, pp. 3588–3591, 1999. View at Google Scholar · View at Scopus
  82. L. Girnita, A. Girnita, M. Wang, J. M. Meis-Kindblom, L. G. Kindblom, and O. Larsson, “A link between basic fibroblast growth factor (bFGF) and EWS/FLI-1 in Ewing's sarcoma cells,” Oncogene, vol. 19, no. 37, pp. 4298–4301, 2000. View at Google Scholar · View at Scopus
  83. D. P. M. Hughes, D. G. Thomas, T. J. Giordano, L. H. Baker, and K. T. McDonagh, “Cell surface expression of epidermal growth factor receptor and her-2 with nuclear expression of Her-4 in primary osteosarcoma,” Cancer Research, vol. 64, no. 6, pp. 2047–2053, 2004. View at Publisher · View at Google Scholar · View at Scopus
  84. R. Ganti, S. X. Skapek, J. Zhang et al., “Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma,” Modern Pathology, vol. 19, no. 9, pp. 1213–1220, 2006. View at Publisher · View at Google Scholar · View at Scopus
  85. J. R. Sampson, “Therapeutic targeting of mTOR in tuberous sclerosis,” Biochemical Society Transactions, vol. 37, no. 1, pp. 259–264, 2009. View at Publisher · View at Google Scholar · View at Scopus
  86. S. Umeoka, T. Koyama, Y. Miki, M. Akai, K. Tsutsui, and K. Togashi, “Pictorial review of tuberous sclerosis in various organs,” Radiographics, vol. 28, no. 7, article e32, 2008. View at Publisher · View at Google Scholar · View at Scopus
  87. K. P. Boyd, B. R. Korf, and A. Theos, “Neurofibromatosis type 1,” Journal of the American Academy of Dermatology, vol. 61, no. 1, pp. 1–14, 2009. View at Publisher · View at Google Scholar · View at Scopus
  88. D. Katz, A. Lazar, and D. Lev, “Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways,” Expert Reviews in Molecular Medicine, vol. 11, p. e30, 2009. View at Google Scholar · View at Scopus
  89. S. Mateo-Lozano, P. C. Gokhale, V. Soldatenkov, A. Dritschilo, O. M. Tirado, and V. Notario, “Combination therapy targeting EWS/FLI-1 oncogene induces apoptosis of Ewing’s sarcoma cells in vitro and inhibits tumor growth in vivo,” Clinical Cancer Research, vol. 12, pp. 6781–6790, 2006. View at Google Scholar
  90. P. J. Houghton, C. L. Morton, R. Gorlick et al., “Stage 2 combination testing of rapamycin with cytotoxic agents by the pediatric preclinical testing program,” Molecular Cancer Therapeutics, vol. 9, no. 1, pp. 101–112, 2010. View at Publisher · View at Google Scholar · View at Scopus
  91. S. Schuetze, L. Zhao, and R. Chugh, “Results of a phase II trial of sirolimus (S) and cyclophosphamide (C) in advanced sarcoma,” Journal of Clinical Oncology, vol. 29, Abstract 10003, 2011. View at Google Scholar
  92. L. Dudkin, M. B. Dilling, P. J. Cheshire et al., “Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition,” Clinical Cancer Research, vol. 7, no. 6, pp. 1758–1764, 2001. View at Google Scholar · View at Scopus
  93. X. Wan, N. Shen, A. Mendoza, C. Khanna, and L. J. Helman, “CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1α/VEGF signaling,” Neoplasia, vol. 8, no. 5, pp. 394–401, 2006. View at Publisher · View at Google Scholar · View at Scopus
  94. S. Okuno, H. Bailey, M. R. Mahoney et al., “A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the mayo phase 2 Consortium (P2C),” Cancer, vol. 117, no. 15, pp. 3468–3475, 2011. View at Publisher · View at Google Scholar · View at Scopus
  95. B. Geoerger, M. W. Kieran, S. Grupp et al., “Phase II study of temsirolimus in children with high-grade glioma, neuroblastoma, and rhabdomyosarcoma,” Journal of Clinical Oncology, vol. 28, no. 15S, abstract 9541, 2010. View at Google Scholar
  96. E. Hernando, E. Charytonowicz, M. E. Dudas et al., “The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas,” Nature Medicine, vol. 13, no. 6, pp. 748–753, 2007. View at Publisher · View at Google Scholar · View at Scopus
  97. S. Richter, D. Pink, P. Hohenberger et al., “Multicenter, triplearm, single-stage, phase II trial to determine the efficacy and safety of everolimus (RAD001) in patients with refractory bone or soft tissue sarcomas including GIST,” Journal of Clinical Oncology, vol. 28, no. 15S, abstract 10038, 2010. View at Google Scholar
  98. R. M. Squillace, D. Miller, M. Cookson et al., “Antitumor activity of ridaforolimus and potential cell cycle determinants of sensitivity in sarcoma and endometrial cancer models,” Molecular Cancer Therapeutics, vol. 10, pp. 1959–1968, 2011. View at Google Scholar
  99. S. P. Chawla, A. P. Staddon, L. H. Baker et al., “Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas,” Journal of Clinical Oncology, vol. 30, no. 1, pp. 78–84, 2012. View at Google Scholar
  100. S. P. Chawla, J. Blay, I. L. Ray-Coquard et al., “Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT),” Annals of Oncology, vol. 29, abstract 10005, 2011. View at Google Scholar
  101. A. J. Wagner, I. Malinowska-Kolodziej, J. A. Morgan et al., “Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors,” Journal of Clinical Oncology, vol. 28, no. 5, pp. 835–840, 2010. View at Publisher · View at Google Scholar · View at Scopus
  102. A. Italiano, C. Delcambre, I. Hostein et al., “Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa perivascular epithelioid cell tumors (PEComas) are rare,” Annals of Oncology, vol. 21, no. 5, pp. 1135–1137, 2010. View at Publisher · View at Google Scholar · View at Scopus
  103. V. Subbiah, J. C. Trent, and R. Kurzrock, “Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors,” Journal of Clinical Oncology, vol. 28, no. 24, p. e415, 2010. View at Publisher · View at Google Scholar · View at Scopus
  104. M. Sáinz-Jaspeado, J. Martin-Liberal, L. Lagares-Tena, S. Mateo-Lozano, X. Garcia-del-Muro, and O. M. Tirado, “Caveolin-1 in sarcomas: friend or foe?” Oncotarget, vol. 2, pp. 305–312, 2011. View at Google Scholar
  105. G. A. McArthur, G. D. Demetri, A. Van Oosterom et al., “Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: imatinib target exploration consortium study B2225,” Journal of Clinical Oncology, vol. 23, no. 4, pp. 866–873, 2005. View at Publisher · View at Google Scholar · View at Scopus
  106. P. Rutkowski, M. Van Glabbeke, C. J. Rankin et al., “Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials,” Journal of Clinical Oncology, vol. 28, no. 10, pp. 1772–1779, 2010. View at Publisher · View at Google Scholar · View at Scopus
  107. J. D. G. Goldberg, E. Choy, L. Rosen et al., “Preliminary results from a phase II study of ARQ197 in patients with microphthalmia transcription family (MiT)-associated tumors,” Journal of Clinical Oncology, vol. 27, abstract 10502, 2009. View at Google Scholar
  108. H. V. Erkizan, Y. Kong, M. Merchant et al., “A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma,” Nature Medicine, vol. 15, no. 7, pp. 750–756, 2009. View at Publisher · View at Google Scholar · View at Scopus
  109. C. J. Breitbach, J. Burke, D. Jonker et al., “Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans,” Nature, vol. 477, pp. 99–102, 2011. View at Google Scholar
  110. G. Li, H. Kawashima, A. Ogose et al., “Efficient virotherapy for osteosarcoma by telomerase-specific oncolytic adenovirus,” Journal of Cancer Research and Clinical Oncology, vol. 137, no. 6, pp. 1037–1051, 2011. View at Publisher · View at Google Scholar · View at Scopus
  111. R. T. Kurmasheva, L. Dudkin, C. Billups, L. V. Debelenko, C. L. Morton, and P. J. Houghton, “The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma,” Cancer Research, vol. 69, no. 19, pp. 7662–7671, 2009. View at Publisher · View at Google Scholar · View at Scopus
  112. F. Huang, A. Greer, W. Hurlburt et al., “The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors,” Cancer Research, vol. 69, no. 1, pp. 161–170, 2009. View at Publisher · View at Google Scholar · View at Scopus
  113. A. S. Martins, J. L. Ordoñez, A. García-Sánchez et al., “A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study,” Cancer Research, vol. 68, no. 15, pp. 6260–6270, 2008. View at Publisher · View at Google Scholar · View at Scopus
  114. R. Quek, Q. Wang, J. A. Morgan et al., “Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors,” Clinical Cancer Research, vol. 17, no. 4, pp. 871–879, 2011. View at Publisher · View at Google Scholar · View at Scopus
  115. A. Naing, R. Kurzrock, A. Burger et al., “Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer,” Clinical Cancer Research, vol. 17, pp. 6052–6060, 2011. View at Google Scholar
  116. J. E. Butrynski, D. R. D'Adamo, J. L. Hornick et al., “Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor,” New England Journal of Medicine, vol. 363, no. 18, pp. 1727–1733, 2010. View at Publisher · View at Google Scholar · View at Scopus
  117. A. Zibat, E. Missiaglia, A. Rosenberger et al., “Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma,” Oncogene, vol. 29, no. 48, pp. 6323–6330, 2010. View at Publisher · View at Google Scholar · View at Scopus
  118. M. Hirotsu, T. Setoguchi, H. Sasaki et al., “Smoothened as a new therapeutic target for human osteosarcoma,” Molecular Cancer, vol. 9, article 5, 2010. View at Publisher · View at Google Scholar · View at Scopus
  119. T. D. Tiet, S. Hopyan, P. Nadesan et al., “Constitutive Hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation,” American Journal of Pathology, vol. 168, no. 1, pp. 321–330, 2006. View at Publisher · View at Google Scholar · View at Scopus
  120. J. Joo, L. Christensen, K. Warner et al., “GLI1 is a central mediator of EWS/FLI1 signaling in Ewing Tumors,” PLoS ONE, vol. 4, no. 10, Article ID e7608, 2009. View at Publisher · View at Google Scholar · View at Scopus
  121. E. Beauchamp, G. Bulut, O. Abaan et al., “GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein,” Journal of Biological Chemistry, vol. 284, no. 14, pp. 9074–9082, 2009. View at Publisher · View at Google Scholar · View at Scopus
  122. J. Roma, A. Masià, J. Reventós, J. S. De Toledo, and S. Gallego, “Notch pathway inhibition significantly reduces rhabdomyosarcoma invasiveness and mobility in vitro,” Clinical Cancer Research, vol. 17, no. 3, pp. 505–513, 2011. View at Publisher · View at Google Scholar · View at Scopus
  123. M. Tanaka, T. Setoguchi, M. Hirotsu et al., “Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulation,” British Journal of Cancer, vol. 100, no. 12, pp. 1957–1965, 2009. View at Publisher · View at Google Scholar · View at Scopus
  124. E. R. Sampson, V. Amin, E. M. Schwarz, R. J. O'Keefe, and R. N. Rosier, “The histone deacetylase inhibitor vorinostat selectively sensitizes fibrosarcoma cells to chemotherapy,” Journal of Orthopaedic Research, vol. 29, no. 4, pp. 623–632, 2011. View at Publisher · View at Google Scholar · View at Scopus
  125. L. Su, H. Cheng, A. V. Sampaio, T. O. Nielsen, and T. M. Underhill, “EGR1 reactivation by histone deacetylase inhibitors promotes synovial sarcoma cell death through the PTEN tumor suppressor,” Oncogene, vol. 29, no. 30, pp. 4352–4361, 2010. View at Publisher · View at Google Scholar · View at Scopus
  126. A. Hrzenjak, F. Moinfar, M. L. Kremser et al., “Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo,” Molecular Cancer, vol. 9, article 49, 2010. View at Publisher · View at Google Scholar · View at Scopus
  127. T. O. Nielsen, A. Nguyen, L. Su, B. Campbell, and N. M. Poulin, “Synergism of heat shock protein 90 and histone deacetylase inhibitors in synovial sarcoma,” Sarcoma, vol. 2009, Article ID 794901, 2009. View at Publisher · View at Google Scholar · View at Scopus
  128. J. M. Lubieniecka, D. R. H. De Bruijn, L. Su et al., “Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma,” Cancer Research, vol. 68, no. 11, pp. 4303–4310, 2008. View at Publisher · View at Google Scholar · View at Scopus
  129. M. C. Manara, G. Nicoletti, D. Zambelli et al., “NVP-BEZ235 as a new therapeutic option for sarcomas,” Clinical Cancer Research, vol. 16, no. 2, pp. 530–540, 2010. View at Publisher · View at Google Scholar · View at Scopus
  130. C. R. Müller, E. B. Paulsen, P. Noordhuis, F. Pedeutour, G. Sæter, and O. Myklebost, “Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A,” International Journal of Cancer, vol. 121, no. 1, pp. 199–205, 2007. View at Publisher · View at Google Scholar · View at Scopus
  131. M. S. Brassesco, M. A. Cortez, E. T. Valera et al., “Cryptic SYT/SXX1 fusion gene in high-grade biphasic synovial sarcoma with unique complex rearrangement and extensive BCL2 overexpression,” Cancer Genetics and Cytogenetics, vol. 196, no. 2, pp. 189–193, 2010. View at Publisher · View at Google Scholar · View at Scopus
  132. O. M. Tirado, S. Mateo-Lozano, and V. Notario, “Roscovitine is an effective inducer of apoptosis of Ewing's sarcoma family tumor cells in vitro and in vivo,” Cancer Research, vol. 65, no. 20, pp. 9320–9327, 2005. View at Publisher · View at Google Scholar · View at Scopus